MD

Business Context and Reporting Period

This summary covers the Form 10-Q filed by MEDNAX, Inc. (Note: The input metadata referenced "Pediatrix Medical Group, Inc.", but the filing text explicitly identifies the registrant as MEDNAX, Inc.) for the quarterly period ended March 31, 2010. MEDNAX is a national provider of physician services, primarily in neonatal, maternal-fetal medicine, and pediatric cardiology, operating through affiliated professional contractors.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 9.6% ($29.0 million). Approximately 76.9% of this increase was driven by acquisitions completed after December 31, 2008. Same-unit revenue grew 2.2%, driven by pricing improvements offset by a slight decline in patient volumes.
• Acquisitions: The company acquired four physician group practices (three neonatal, one maternal-fetal medicine) for total consideration of $46.4 million ($37.4 million cash, $9.0 million contingent). This resulted in $44.5 million of recorded goodwill.
• Operating Expenses: Practice salaries and benefits rose 10.0% due to new staff for acquisitions, partially offset by lower incentive compensation payouts. General and administrative expenses increased 4.0% but decreased as a percentage of revenue to 11.4% due to efficiencies.
• Cash Flow: Net cash used in operating activities increased to $41.6 million (from $22.0 million used in Q1 2009). This was primarily due to a $108.3 million cash outflow for accounts payable and accrued expenses, largely driven by annual performance-based incentive compensation payments made in the first quarter.
• Liquidity: Working capital improved significantly from a $54.0 million deficit at year-end 2009 to a $38.0 million surplus, aided by borrowings under the line of credit.

Outlook, Risks, and Contingencies

• Healthcare Reform: The "Patient Protection and Affordable Care Act" was enacted in March 2010. While it expands Medicaid and creates exchanges, it also introduces payment modifiers based on quality of care. A scheduled 21% Medicare fee reduction is set for June 1, 2010, unless Congress acts to postpone it.
• Economic Environment: The company notes a shift toward government-sponsored programs due to the economic slowdown, which typically reimburse at lower rates than commercial payors. State budget shortfalls may lead to delayed Medicaid reimbursements.
• Legal and Compliance:
  • Corporate Integrity Agreement (CIA): The company is under a five-year CIA with the Office of Inspector General (OIG) following a 2006 settlement regarding billing practices. Failure to comply could result in exclusion from federal healthcare programs.
  • Stock Option Review: The company is cooperating with the U.S. Attorney's office regarding a review of historical stock option granting practices; the outcome is unpredictable.
  • Malpractice: The company self-insures a portion of professional liability risks. Total liability for professional liability risks was $110.4 million as of March 31, 2010.
• Capital Resources: The company has a $350 million revolving credit facility (expandable to $400 million). With $129.0 million outstanding and $6.1 million in letters of credit, $214.9 million remains available. Management believes current resources are sufficient for the next 12 months.

Investor Verification Checklist

• Verify the impact of the potential 21% Medicare fee reduction scheduled for June 1, 2010, on future revenue projections.
• Monitor the integration and performance of the four practices acquired in Q1 2010 to ensure they meet the projected growth and cost-saving targets.
• Review the status of the U.S. Attorney's office investigation into historical stock option practices for potential financial or reputational impact.
• Assess the adequacy of the $110.4 million accrual for professional liability risks given the self-insured nature of the company's malpractice coverage.
• Track Days Sales Outstanding (DSO), which increased to 47.0 days, to ensure collection efficiency remains stable despite higher revenue.